Menu
1. Maintain high medical ethics, as represented by our mission to provide accessible medical care for mankind and enforce this principle through full regulatory compliance in each country where we carry out activities.
2. Become an innovator in the fields of pharmaceutical, health food production, cosmetics, livestock feeds, and fertilizers, and contribute to the advancement of the health and well-being of people through the provision of safe health products and the efficient production of safe food.
3. Develop an organization that flexibly adapts to changes in the operating environment and continue to self-evolve as a corporation that fuses ingenuity and a self-innovating spirit.
4. Recognize our social responsibility as a member of society in each country where we carry out operations and contribute to the advancement of that society, while meeting the demands of various stakeholders
Name
SBI Pharmaceuticals Co., Ltd.
Business
R&D, manufacture and marketing of the medicines and medical devices that utilize 5-ALA (5-aminolevulinic acid)
Address
(Headquarters) Izumi Garden Tower 20F, 1-6-1, Roppongi, Minato-ku, Tokyo 106-6020, Japan, Direct link with Roppongi 1-chome Station,
(Research Institute) Innovation Center of NanoMedicine (iCONM) 4F, 3-25-14 Tono-machi, Kawasaki-ku
Kawasaki-shi, Kanagawa 210-0821, Japan, 15 minute-walk from Kojimashinden Station.
TEL
(Headquarters) Tel: 03-6229-0095; Fax: 03-3589-0761
(Research Institute) Tel: 044-382-0500; Fax: 044-382-0510
Date Founded
April 18, 2008
Capital
100 Million Yen
Directors
Representative Director, President Yoshitaka Kitao
Representative Director, Senior Executive Vice President Ulrich Kosciessa
Director, Executive Officer COO&CFO Kenji Hirai
Director Motowo Nakajima
Director Yasushi Takezaki
Statutory Auditor Hideyuki Katsuchi
July
Laboratory transferred from Setagaya to Kobe
April
Name changed to SBI Pharmaceuticals.
Cosmetic and health food business transferred to newly established company named SBI ALApromo.
Agreement reached with the Bahrein government to proceed with our 5 ALA business.
September
Sale launched of ALAGLIO® Internal Medicine 1.5 g as a Photodynamic diagnostic agent for brain cancer
April
Sale launched of medical light source Bicolor LED Light Source Aladuck LS-DLED
January
Received the Minister of Economy, Trade and Industry Award at the Japan Bio-venture Awards.
February
Received the Seiichi Tejima Invention Award
December
Sale launched of ALAGLIO® Divided Granules 1.5 g as a photodynamic diagnostic agent for bladder cancer.
March
Laboratory transferred from Kobe to Kawasaki.
March
Sale launched of medical light source Aladuck®405/Ⅱ
May
Registered medical light source Aladuck®405/Ⅱ as a classⅡ medical device with the U.S. FDA
About Us
Our Strengths